BioStack Raises $9.5 Million to Expand Healthcare Data Network

BioStack has raised $9.5 million in a seed funding round led by Peak XV, with seven other investors participating: Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. BioStack said the capital will support international expansion, technology development and growth of its engineering and research teams.

Entrackr's report did not disclose a valuation or closing date. It included no revenue, customer or deployment figures.

What is BioStack building?

Founded by Sanat Mishra, healthcare technology startup BioStack is building a healthcare data infrastructure network across the US, India, Brazil and Argentina. The company says its network has access to more than 100 million de-identified patient records.

BioStack connects fragmented clinical information from hospitals and healthcare systems. It creates longitudinal patient records that combine clinical notes, laboratory results, medical imaging, medications, treatment histories and patient outcomes.

The aim is to turn separate records into a continuous view of patient history. Entrackr's report does not explain how BioStack validates record matches, removes duplication or measures data quality. In practical terms, the core product is a longitudinal patient record assembled across institutions.

How does it turn clinical records into datasets?

BioStack says it creates proprietary datasets from de-identified clinical data. Those datasets support medical research, drug development, and the training and evaluation of healthcare AI models, according to the company.

The platform is designed for disease modelling, biomarker discovery, patient stratification and treatment response analysis. It also incorporates workflows tailored to individual healthcare providers and each provider's data privacy protocols.

The company presents tailored workflows as a way to accommodate different provider privacy protocols. The report does not identify provider customers, describe the privacy protocols or say whether the platform holds specific regulatory certifications. The platform's usefulness depends on clean data and workflows that providers can adopt under their own privacy rules.

What scale has BioStack reached?

BioStack claims it has aggregated several hundred thousand X-rays, MRI and CT scans. It also reports millions of telehealth audio transcripts and other clinical records.

The company separately says its four-country network has access to more than 100 million de-identified patient records. Entrackr's report does not reconcile that figure with its aggregation claims, disclose how many records it has processed into proprietary datasets or specify volumes by country. The figures indicate scale, but not how much data has become a usable proprietary product.

Where will the expansion happen?

In India, BioStack is helping connect cancer patients with an investigational cancer vaccine programme. Entrackr's report does not name the programme, identify its sponsor, quantify patient participation or describe BioStack's role beyond connecting patients with it.

The named footprint spans the US, India, Brazil and Argentina. The report does not state which country activities are operating or planned, or allocate the $9.5 million by country. The financing is earmarked for broader geographic reach, but the disclosure does not show which markets are ready to scale.

What does the seed round buy?

BioStack will use the proceeds for international expansion, technology development and growth of its engineering and research teams. The report does not set out hiring targets, product milestones, spending allocations or financial targets.

Peak XV led the round, making it the only investor with a specifically identified role. The report gives no investment amounts, equity stakes, board rights or return terms for Peak XV or the seven other named firms. In practical terms, the round buys capacity, but the disclosure does not establish how BioStack will measure commercial progress.

What remains to be proven?

BioStack presents a broad infrastructure proposition: consolidate fragmented records, create proprietary datasets, and support medical research, drug development and healthcare AI workloads. Entrackr's report provides no evidence on revenue, pricing, customer retention, model performance, research outcomes or commercial adoption.

Entrackr's report also contains no direct statement from founder Sanat Mishra or the investors about targets for the funding. The next test is whether the new capital can convert claimed record access into repeatable deployments across four countries while maintaining provider-specific privacy requirements.